Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $872.30M | $844.90M | $805.00M | $804.60M | $766.50M | $698.00M | $748.80M | $746.90M |
| Cost of revenue | $543.10M | $548.50M | $501.10M | $510.30M | $492.60M | $466.10M | $475.20M | $482.20M |
| Gross profit | $329.20M | $296.40M | $303.90M | $294.30M | $273.90M | $231.90M | $273.60M | $264.70M |
| Gross margin | 37.7% | 35.1% | 37.8% | 36.6% | 35.7% | 33.2% | 36.5% | 35.4% |
| Research and development | $19.70M | $15.80M | $21.80M | $17.10M | $19.10M | $16.30M | $18.50M | $15.50M |
| Selling, general and administrative | $117.60M | $99.50M | $107.00M | $102.70M | $95.90M | $88.00M | $85.30M | $83.50M |
| Operating expenses | $137.30M | $115.30M | $128.80M | $119.80M | $115.00M | $104.30M | $103.80M | $99.00M |
| Operating income | $191.90M | $181.10M | $175.10M | $174.50M | $158.90M | $127.60M | $169.80M | $165.70M |
| Operating margin | 22.0% | 21.4% | 21.8% | 21.7% | 20.7% | 18.3% | 22.7% | 22.2% |
| EBITDA | $238.10M | $226.30M | $222.10M | $217.50M | $200.30M | $167.60M | $210.50M | $205.90M |
| Interest income | $3.80M | $5.10M | $5.10M | $4.70M | $3.60M | $4.10M | $4.80M | $4.60M |
| Interest expense | −$2.60M | −$1.90M | $200.00K | −$200.00K | −$100.00K | −$400.00K | $800.00K | −$700.00K |
| Income before taxes | $186.20M | $180.10M | $161.50M | $171.90M | $162.00M | $110.50M | $164.90M | $164.50M |
| Income taxes | $32.20M | $44.70M | $33.30M | $34.00M | $30.20M | $24.10M | $36.80M | $32.40M |
| Net income | $154.00M | $138.80M | $132.10M | $140.00M | $131.80M | $89.80M | $130.10M | $136.00M |
| Net margin | 17.7% | 16.4% | 16.4% | 17.4% | 17.2% | 12.9% | 17.4% | 18.2% |
| EPS, basic | $2.17 | $1.93 | $1.83 | $1.94 | $1.82 | $1.24 | $1.79 | $1.87 |
| EPS, diluted | $2.15 | $1.92 | $1.82 | $1.92 | $1.82 | $1.23 | $1.77 | $1.85 |
| Diluted shares | 71.30M | 72.40M | 72.70M | 72.60M | 72.50M | 73.00M | 73.40M | 73.40M |
Figures describe West Pharmaceutical Services shares, not any token. As of Jul 23, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.